FV

Francis Vincent Mcnamara Iii

Director Director Appointed In Casual Vacancy DIN 02579309
DIN 02579309 First appointment Feb 2009 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 1 historical roles
Total affiliations 1 Since Feb 2009
Shareholding value β€’β€’β€’β€’ Premium profile

About Francis Vincent Mcnamara Iii

Data last updated:

Francis Vincent Mcnamara Iii was a Director Appointed In Casual Vacancy at Astrazeneca Pharma India Limited (2009–2010). The company operates in Pharma.

DIN 02579309
Primary Designation Director Appointed In Casual Vacancy
Industry Pharma
First Appointment 18 Feb 2009

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Astrazeneca Pharma India Limited L24231KA1979PLC003563
Director Appointed In Casual Vacancy18 Feb 20091979₹1,757 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Astrazeneca Pharma India Limited
Premium access

Shareholding and investment profile for Francis Vincent Mcnamara Iii

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Francis Vincent Mcnamara Iii

Francis Vincent Mcnamara Iii was first appointed on 18 Feb 2009 as Director Appointed In Casual Vacancy at Astrazeneca Pharma India Limited.

Francis Vincent Mcnamara Iii held 1 earlier board appointment: Astrazeneca Pharma India Limited (Director Appointed In Casual Vacancy, 18 Feb 2009 to 30 Sep 2010).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available